| 영문 | fulminant hepatitis | 한글 | 전격간염 |
|---|---|---|---|
| 설명 | 바이러스 간염의 한 형으로 급성 황색위축증이라고도 부른다. 간세포의 대부분이 괴사상태로 되며 환자는 보통 사망한다. 황달이 나타나기 전부터 이미 증상은 현저히 진행하여 황달의 출현도 빠르고, 급성 발열을 수반하며 점막이나 피하출혈을 볼 수 있다. 간의 압통을 수반하는 수도 있다. 위축에 의하여 간은 자주 작아진다. 최후에는 의식장애를 초래하여 졸음이 오고 혼미상태로 되며 간성혼수로 진행하여 사망하게 된다. 증상이 시작되어 2~3주 내에 간뇌병증까지 진행하는 간기능 상실을 전격성 간기능상실이라고 부르며, 진행 속도가 빠르지 않아서 3개월에 이르러 간기능상실에 빠지는 것은 아급성 간기능상실이라고 부른다. 모든 간염 바이러스가 모두 일으키지는 않는다. 간염A바이러스와 간염E바이러스는 보유자 상태나 만성 간염을 거의 일으키지 않는다. 기타 다른 감염 또는 비감염성 원인, 특히 약물과 독소도 본질적으로 동일한 증후를 일으킬 수 있다. 그러므로 바이러스성 간염의 진단과 각 간염 바이러스를 구별하는데는 혈청학적 검사가 필수적이다. |
||
| AH | abdominal hysterectomy; absorptive hypercalciuria; accidental hypothermia; acetohexamide; acid hydro... |
|---|---|
| HLA | histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod... |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| HAA | hearing aid amplifier; hemolytic anemia antigen; hepatitis-associated antigen; hospital activity ana... |
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| core plasma | <radiobiology> Hot plasma at the centre of a fusion reactor, distinguished from edge plasma and scrape-off layer (SOL). The core plasma does not directly feel the effects of the divertor or limiter in the way the edge plasma does. (09 Oct 1997) |
|---|---|
| core pneumonia | A form of pneumonia in which exudation is confined for a time to the central portion of a lobe or the hilar region. Synonym: core pneumonia. (05 Mar 2000) |
| post and core technique | Use of a metal casting, usually with a post in the pulp or root canal, designed to support and retain an artificial crown. (12 Dec 1998) |
| HIV core protein p24 | A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by elisa and western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines. (12 Dec 1998) |
| disease, central core, of muscle | <anatomy> One of the conditions that produces 'floppy baby' syndrome. CCD causes hypotonia (floppiness) in the newborn baby, slowly progressive muscle weakness, and muscle cramps after exercise. Muscle biopsy shows a key diagnostic finding (absent mitochondria in the centre of many type I muscle fibres). CCD is inherited as a dominant trait. The CCD gene is on chromosome 19 (and involves ryanodine receptor-1). (12 Dec 1998) |
| acute parenchymatous hepatitis | A lesion in which there is extensive and rapid death of parenchymal cells of the liver, sometimes with fatty degeneration of the size of the organ; the necrosis may result from fulminant viral infection or chemical poisoning; associated with jaundice. Synonym: acute parenchymatous hepatitis, Rokitansky's disease. (05 Mar 2000) |
| anicteric hepatitis | Hepatitis without jaundice. (05 Mar 2000) |
| anicteric virus hepatitis | A relatively mild hepatitis, without jaundice, due to a virus; the principal physical signs and symptoms are enlargement of the liver, lymph nodes, and often the spleen, together with headache, continuous fatigue, nausea, anorexia, sudden distaste for smoking, abdominal pains, and sometimes mild fever; labratory tests reveal evidence of hepatitis. (05 Mar 2000) |
| autoimmune hepatitis | <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver. Symptoms are those of chronic active hepatitis. (27 Sep 1997) |
| vaccination, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |
| vaccination, hepatitis b | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| vaccination, infectious hepatitis | See Vaccination, hepatitis a. (12 Dec 1998) |
| vaccineation, serum hepatitis | See Vaccination, hepatitis b. (12 Dec 1998) |
| giant cell hepatitis | Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop. Synonym: giant cell hepatitis. (05 Mar 2000) |
| viral hepatitis | Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver. (12 Dec 1998) |